BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday. The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.
About the Author
